DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Detalles Bibliográficos
Autores principales: Kizhakeyil, Atish, Zaini, Nurmahirah Binte Mohammed, Poh, Zhi Sheng, Wong, Brandon Han Siang, Loh, Xinpeng, Ng, Aik Seng, Low, Zun Siong, Prasannan, Praseetha, Gong, Chun, Tan, Michelle Guet Khim, Nagarajan, Chandramouli, Huang, Dachuan, Lu, Pang Wan, Lim, Jing Quan, Barrans, Sharon, Ong, Choon Kiat, Lim, Soon Thye, Chng, Wee Joo, Follows, George, Hodson, Daniel J., Du, Ming Qing, Goh, Yeow Tee, Tan, Suat Hoon, Grigoropoulos, Nicholas Francis, Verma, Navin Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520256/
https://www.ncbi.nlm.nih.gov/pubmed/34654425
http://dx.doi.org/10.1186/s12943-021-01437-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520256/
https://www.ncbi.nlm.nih.gov/pubmed/34654425
http://dx.doi.org/10.1186/s12943-021-01437-0

Ejemplares similares